Omada Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Omada Health, Inc. on August 6, 2026. The filing primarily addresses a significant leadership transition and references the company's financial results for the three months ended June 30, 2026, which were announced via a press release incorporated as Exhibit 99.1.
Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and are not detailed in the body of this 8-K document.
Material Changes
The primary material change disclosed is a planned executive leadership transition effective January 1, 2027:
- Sean Duffy: Current Chief Executive Officer (CEO) will transition to Executive Chairman of the Board.
- Wei-Li Shao: Current President will succeed Mr. Duffy as CEO.
- Board Composition: Mr. Shao will be appointed as a Class I director effective on the transition date.
- Lead Independent Director: Jeryl Hilleman will be appointed as Lead Independent Director effective on the transition date, succeeding her role as Chairperson.
Both Mr. Duffy and Mr. Shao will continue in their current roles until the transition date.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, outlook statements, or risk factors within the text provided. It notes that no compensation changes have been approved in connection with the leadership transition as of the filing date. The press release referenced in Item 2.02 may contain additional management commentary regarding the financial results for the quarter ended June 30, 2026.
Key Facts for Investor Verification
- Verify the specific financial performance metrics (revenue, net income, cash flow) for the quarter ended June 30, 2026, by reviewing the attached press release (Exhibit 99.1).
- Confirm the effective date of the leadership transition is January 1, 2027.
- Monitor future filings for details on compensation arrangements for the new CEO and Executive Chairman, as none were approved at the time of this filing.
- Note the change in board structure with Wei-Li Shao becoming a director and Jeryl Hilleman assuming the Lead Independent Director role.